Chronic kidney disease (CKD) is a common1 yet widely underrecognized and potentially deadly condition2,3 and is estimated to affect more than 160 million people with type 2 diabetes (T2D) worldwide.4,5,6 CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced.7,8
Regular testing for the earliest signs of kidney disease is essential to slow progression.9 The KDIGO, ADA, and EASD guidelines recommend testing both eGFR and UACR at least once a year in patients with CKD and T2D.9,10,11 What’s more, a multidisciplinary approach to care can improve outcomes for patients with CKD and T2D and help spot the earliest signs of disease progression.
Hear from leading experts below on how outcomes can be improved for patients living with CKD and T2D, alongside insights from their experience and best practices.
Professor Peter Rossing
Head of Complications Research at Steno Diabetes Center Copenhagen, Denmark
Professor Carolyn Lam
Senior Consultant of the National Heart Centre, Singapore
Primary Care Physician
Professor Richard Hobbs
Nuffield Professor of Primary Care Health Sciences, UK
Professor Christoph Wanner
Professor of Medicine and Head of the Division of Nephrology University Hospital of Würzburg, Germany
Integrated care and consistent communication are essential to improve patient care. Learn how a multidisciplinary approach can improve outcomes for patients with CKD and T2D.
A panel discussion on chronic kidney disease in T2D with four key opinion leaders.
Professor Carolyn Lam (Senior Consultant of the National Heart Centre, Singapore) and Professor Richard Hobbs (Nuffield Professor of Primary Care Health Sciences,UK) discuss the close link between CKD and T2D.
The panel discusses the type of tests and the testing protocols that are involved in diagnosing CKD early.
The panel discusses the key challenges when clinicians discuss kidney health with patients with CKD and T2D.
The panel discusses the different roles of health care providers to support the management of patients with CKD and T2D as a broader team.